Siili Solutions Plc Announcement 1.7.2025 Siili Solutions Plc: Share Repurchase 1.7.2025 In the Helsinki Stock Exchange Trade date 1.7.2025 Bourse trade Buy Share SIILI Amount 1 000SharesAverage price/ share 6,4020EURTotal cost 6 402,00EUR Siili Solutions Plc now holds a total of 21 318 shares<td colspan="2" sty ...

ST板块持续上行，成为近期A股市场表现最好的板块之一。 近期ST板块取得较好表现，万得ST板块指数已录得"七连阳"。而拉长时间来看，年内一些ST股累计涨幅更是惊人。行情数据显示，*ST宇顺（002289） 年内涨幅超过370%，*ST信通（600289）年内涨幅超过280%，此外，*ST亚振（603389）、ST华通（002602）、ST迪威迅（300167）等多股股价年内已 经翻倍。 值得注意的是，尽管近期ST板块连续走强，但整个板块的行情仍是结构性的，投资者也需留意盲目投资ST股的相关风险。 ST板块"七连阳"逾八成股票强势上涨 行情数据显示，自6月23日开始，表征ST板块走势的万得ST板块指数已录得"七连阳"，上述区间累计涨幅达4.74%，超过同期上证指数和深证成指的涨 幅。 | F9 不想权 超级带加 画线 丁具 谷 >> | | | 1042.08 +10.81 +1.05% | | | | ST板块指数 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025/05/06-2025/07/01 (40日) ▼ | D | ...

鲍威尔发声。 当地时间周二，美联储主席杰罗姆·鲍威尔表示，若不是美国总统唐纳德·特朗普的关税计划，美联储本 会采取更宽松的货币政策。 据CNBC报道，在一场小组讨论中，当被问及如果特朗普今年早些时候没有宣布所谓"对等关税"，美联 储是否会再次降息时，鲍威尔回答称："我认为是这样的。" 鲍威尔补充道："实际上，当我们看到关税的规模时，我们暂停了行动，而且本质上，由于关税，美国 所有的通胀预测都大幅上升。" 鲍威尔预计，受关税影响，今夏通胀将小幅走高，因此在经济依然稳健的情况下，美联储选择保持耐 心，等待是最审慎的做法。鲍威尔称，无法断言7月降息是否为时过早，但强调"不会预先排除任何一次 会议采取行动的可能性"，下一步行动将完全取决于数据表现。此外，鲍威尔表示，绝大多数美联储委 员预计今年晚些时候会降息。 根据芝加哥商品交易所（CME）的美联储观察工具，联邦基金期货交易员认为，美联储在7月政策会议 上再次维持利率不变的可能性超过76%。 在6月的议息会议上，美联储宣布将再次维持关键借贷利率不变。自去年12月以来，美联储一直维持利 率在4.25%—4.5%的区间不变。今年以来，特朗普频频施压美联储降息。 当地时间6 ...

多家车企公布了6月销售数据。 7月1日，多家车企公布了6月销售数据。 鸿蒙智行数据显示，6月单月全系交付52747辆，单日交付量3651辆，分别刷新鸿蒙智行单月、单日销量历史新高。鸿蒙智行今日称，迎来交付量爆发 期，仅用39个月实现全系累计交付80万辆，创下新势力汽车最快交付纪录。 目前，鸿蒙智行已有"四界"产品上市，分别是华为和赛力斯合作的问界、与奇瑞合作的智界、与北汽合作的享界、与江淮合作的尊界。 2025年2月，上汽集团与华为签订深度合作协议，联合打造新能源智能汽车品牌"尚界"，成为了鸿蒙智行的第五"界"。此前，在5月31日召开的未来汽 车先行者大会上，华为常务董事、终端BG董事长余承东曾透露，目前鸿蒙智行已经有"五界"，但可能也就到此截止了。 小米汽车公布数据显示，6月交付量超过25000辆，此前，在今年4月、5月，小米汽车交付量连续突破28000辆。今年3月底，一场小米SU7交通事故引 发巨大舆论，此后小米SU7 Ultra"挖孔门"持续发酵，引发热议。 不过，6月26日，小米首款SUV车型YU7正式发布上市，起售价25.35万元，该款车型上市即取得亮眼"战报"，成为又一"现象级"产品。小米汽车官微 ...

Tuesday, July 1, 2025The first half of calendar 2025 (1H25) ended yesterday at record highs on the major stock market indexes, but early trading ahead of the first session of 2H25 is giving some of these gains back. As investors clear the sleep from their eyes, we see a giant tax bill still being decided on in the Senate, little progress on trade deals ahead of the July 9 tariff deadline, and pending jobs numbers that have shown a bit of unraveling in the past weeks and months.Expectations are still favorab ...

Group 1: Electric Vehicle Sales Performance - Ford experienced a 31% decline in U.S. electric vehicle sales in Q2 2025, primarily due to a significant drop in E-Transit vans and reduced interest in the F-150 Lightning [1] - Year-to-date, Ford has sold 38,988 electric vehicles, reflecting a nearly 12% decrease compared to the same period in 2024, despite overall sales increasing due to aggressive employee pricing promotions [2] - The Mustang Mach-E sales fell nearly 20% year-over-year to 10,178 units, while F-150 Lightning sales dropped by 26% to 5,842 units [4] Group 2: Market Challenges and Competitor Performance - The U.S. electric vehicle market is facing challenges, with potential federal tax incentive removals under the Trump administration, impacting overall sales [3] - Competitors like Hyundai reported declines in their electric vehicle sales, with Ioniq 5 and Ioniq 6 down 12% and 8% respectively, while Kia's EV9 and EV6 saw even steeper drops [3] - Ford's E-Transit sales plummeted to 418 units from 3,410 in Q2 2024, attributed to larger fleet orders being placed earlier in the year [4] Group 3: Future Outlook - Ford is developing a lower-cost range of electric vehicles, starting with a small truck, but these are not expected to be available until 2027 [4]

Group 1 - The company *ST Aowei (002231) announced that its subsidiary, Wuxi Donghexin New Materials Industry Co., Ltd., suffered a loss of approximately 25.04 million yuan due to poor management of production materials by Jiangsu Dajiang Metal Materials Co., Ltd. [1] - The company plans to take legal action against Jiangsu Dajiang and other related parties to seek compensation for the losses incurred [1]. - Jiangsu Dajiang is identified as a related party due to its connection with the company's controlling shareholder and actual controller [1]. Group 2 - The company is facing unresolved issues regarding the occupation of funds by shareholders, with an outstanding balance of 208 million yuan as of the end of 2024 [2]. - Adjustments to the occupied funds have been made, resulting in a total receivable amount of 197 million yuan from Shanghai Donghexin and its related parties [2]. - As of June 30, 2025, a total of 184 million yuan in occupied funds remains unpaid, despite multiple reminders sent to the controlling shareholders [2]. Group 3 - The company's metal products business is currently suspended and is not expected to resume normal operations within three months [3]. - The company's stock trading has been subjected to additional risk warnings due to these operational challenges [3].

此前在2024年，越秀资本已经授权过一次广州资产对越秀地产的增持行动。彼时越秀资本同意广州资产 使用不超过5.57亿元的自有资金增持越秀地产，至授权期限结束，广州资产实际买入越秀地产港股股票 7838万股，占越秀地产总股份数目的1.95%，累计使用资金3.52亿元。 越秀资本（000987）7月1日宣布，同意公司控股子公司广州资产使用不超过2.04亿元自有资金，通过港 股通在二级市场增持越秀地产港股股票(股票代码：00123.HK)，授权期限为本次董事会审议通过之日起 至2026年5月30日。本次交易构成关联交易。 在经营策略上，越秀地产聚焦粤港澳大湾区及华东、中西部、北方地区，深耕一线城市和重点二线城 市。据中指研究院统计，上半年越秀地产斥资105亿元拿地，其中34亿元集中在粤港澳大湾区，在这一 区域拿地金额仅次于保利置业，位居行业第二。 在4月的杭州土拍中，越秀地产经过82轮竞价，以58.23%的溢价率，总价11.00亿元摘得原运河新城单 元-1地块，成交楼面价39146元/㎡，创板块最高纪录，预计未来新房价格在5.5万元/平方米左右。展现 出越秀地产对核心区稀缺地块的争夺热情及对改善型产品的信心。 本次 ...

拉卡拉（300773）7月1日晚间公告，大股东联想控股计划减持上市公司不超过总股本3%的股份。联想 控股目前持股比例为26.54%。 拉卡拉7月1日股价下跌8.1%，但较5月28日收盘价仍上涨61%。该公司近期股价上涨的背景是稳定币相 关概念热度飙升。 据披露，联想控股计划在自公告之日起的15交易日后的3个月内(2025年7月23日至2025年10月22日)以集 中竞价方式减持上市公司股份不超过总股本比例的1%；自公告之日起15个交易日后的3个月内以大宗交 易方式合计减持不超过总股本比例的2%。 联想控股表示，减持价格根据减持时的市场价格确定，减持是由于自身业务安排及需要。 近期除联想控股计划减持，拉卡拉还迎来一位重要股东的减持计划。 5月20日，拉卡拉曾公告称，持有公司股份1927万股(占剔除回购股份后公司总股本比例为2.45%)的股东 孙浩然计划减持，减持数量不超过1927万股。 据拉卡拉的IPO招股书披露，孙浩然与拉卡拉创始人孙陶然为兄弟关系。 拉卡拉2019年上市，其前身是创始人孙陶然与有道创投、雷军等共同出资创办的乾坤时代，为中国最早 的第三方支付公司之一。 2008年，联想控股以现金+资产的方式注 ...

CNM-Au8 Therapeutic Potential - Clene is pioneering catalytic nanotherapeutics to treat neurodegenerative diseases like ALS, Parkinson's, and MS[13] - CNM-Au8 is a nanocrystal suspension administered orally, targeting energy metabolism and oxidative stress, and can penetrate the blood-brain barrier[27] - CNM-Au8 contains >100 trillion nanocrystals per 60 mL dose (at 30 mg)[24] - Over 800 participant-years of exposure to CNM-Au8 with predominantly mild-to-moderate TEAEs and no related SAEs across all clinical programs[36] ALS Clinical Trial Outcomes - In the HEALEY ALS Platform Trial, CNM-Au8 30 mg showed a 94% risk reduction in time to death or PAV during the double-blind period[41] - During the OLE to Month 12 of the HEALEY ALS Platform Trial, CNM-Au8 30 mg showed a 78% risk reduction in time to death or PAV[46] and a 62% risk reduction in time to death[48] - A 71% risk reduction in delayed time to clinical worsening was observed in two independent Phase 2 trials[50] - Participants with NfL decline at Week 24 in the HEALEY ALS Platform Trial showed a 91% risk reduction in time to death or PAV[92] MS Clinical Trial Outcomes - In MS patients on DMTs, CNM-Au8 demonstrated significantly improved vision as measured by Change in Low Contrast Letter Acuity (LCLA)[124] - CNM-Au8 demonstrated global neurological improvement in stable MS patients on DMTs[123] Financial Status - As of March 31, 2025, Clene Inc had $9.8 million in cash and equivalents on hand (unaudited)[178]